| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
In N2a cells, PrP (106–126) (100 μM) gradually causes mTOR phosphorylation. The production of ROS is substantially higher in cells treated with PrP (106–126) than in control cells treated with PBS. Apoptosis elicited by PrP (106–126) is enhanced by PRAS40 knockdown. By activating mTOR and AKT, PRAS40 reduces the neuronal apoptosis caused by PrP (106–126)[1]. PrP (106–126) preferentially interacts with PBECs via their luminal side, resulting in cumulative cell death as demonstrated by the release of lactate dehydrogenase, decrease of 3-(4,5-dimethylthiazol-2-yl)–2,5-diphenyltetrazolium bromide, induction of Caspase 3 and direct cell counting. Furthermore, while the PBEC maintained confluency, PrP (106–126) but not its corresponding scrambled peptide causes a 50% decrease in trans-endothelial electrical resistance[2].
|
|---|---|
| References |
[1]. Yang W, et al. PRAS40 alleviates neurotoxic prion peptide-induced apoptosis via mTOR-AKT signaling. CNS Neurosci Ther. 2017 May;23(5):416-427.
[2]. Cooper I, et al. Interactions of the prion peptide (PrP 106-126) with brain capillary endothelial cells: coordinated cell killing and remodeling of intercellular junctions. J Neurochem. 2011 Feb;116(4):467-75 |
| Molecular Formula |
C80H138N26O24S2
|
|---|---|
| Molecular Weight |
1912.30
|
| Exact Mass |
1910.98
|
| CAS # |
148439-49-0
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
0.334
|
| SMILES |
C(O)(=O)CNC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC1N=CNC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@H](CCCCN)N
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 1 mg/mL (0.52 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (52.29 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.5229 mL | 2.6147 mL | 5.2293 mL | |
| 5 mM | 0.1046 mL | 0.5229 mL | 1.0459 mL | |
| 10 mM | 0.0523 mL | 0.2615 mL | 0.5229 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
